MSX-3

• CAT Number: I032839
• CAS Number: 261717-23-1
• Molecular Formula: C21H21N4Na2O7P
• Molecular Weight: 518.37
• Purity: 98%
• Synonyms: MSX-3; MSX 3; MSX3
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 3,7-Dihydro-8-[(1E)-2-(3-methoxyphenyl)ethenyl]-7-methyl-3-[3-(phosphonooxy)propyl]-1-(2-propynyl)-1H-purine-2,6-dione Disodium Salt
• InChI: InChI=1S/C21H23N4O7P.2Na/c1-4-11-25-20(26)18-19(24(21(25)27)12-6-13-32-33(28,29)30)22-17(23(18)2)10-9-15-7-5-8-16(14-15)31-3;;/h1,5,7-10,14H,6,11-13H2,2-3H3,(H2,28,29,30);;/q;2*+1/p-2/b10-9+
• InChIKey: ZYVZWCILYQDHNU-TTWKNDKESA-L
• SMILES: O=C(N1CC#C)N(CCCOP([O-])([O-])=O)C2=C(N(C)C(/C=C/C3=CC=CC(OC)=C3)=N2)C1=O.[Na+].[Na+]

MSX-3 (Cat.No:I032839) is a small molecule compound that has been studied for its potential pharmacological effects. It acts as an antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), which is involved in regulating synaptic transmission in the brain. MSX-3 has shown promising results in preclinical studies as a potential treatment for neurodegenerative disorders and addictive behaviors. However, further research is needed to fully understand its therapeutic potential and safety profile.

Reference

1: Agosto-Marlin IM, Nichols NL, Mitchell GS. Adenosine-dependent phrenic motor facilitation is inflammation resistant. J Neurophysiol. 2017 Feb 1;117(2):836-845. doi: 10.1152/jn.00619.2016. Epub 2016 Dec 7. PubMed PMID: 27927784; PubMed Central PMCID: PMC5315699.
2: López-Cruz L, San-Miguel N, Bayarri P, Baqi Y, Müller CE, Salamone JD, Correa M. Ethanol and Caffeine Effects on Social Interaction and Recognition in Mice: Involvement of Adenosine A(2A) and A(1) Receptors. Front Behav Neurosci. 2016 Nov 2;10:206. eCollection 2016. PubMed PMID: 27853423; PubMed Central PMCID: PMC5090123.
3: Yohn SE, Arif Y, Haley A, Tripodi G, Baqi Y, Müller CE, Miguel NS, Correa M, Salamone JD. Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. Psychopharmacology (Berl). 2016 Oct;233(19-20):3575-86. doi: 10.1007/s00213-016-4392-9. Epub 2016 Aug 6. PubMed PMID: 27497935.
4: Devinney MJ, Nichols NL, Mitchell GS. Sustained Hypoxia Elicits Competing Spinal Mechanisms of Phrenic Motor Facilitation. J Neurosci. 2016 Jul 27;36(30):7877-85. doi: 10.1523/JNEUROSCI.4122-15.2016. PubMed PMID: 27466333; PubMed Central PMCID: PMC4961775.
5: Podurgiel SJ, Spencer T, Kovner R, Baqi Y, Müller CE, Correa M, Salamone JD. Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism. Pharmacol Biochem Behav. 2016 Jan;140:62-7. doi: 10.1016/j.pbb.2015.10.008. Epub 2015 Oct 13. PubMed PMID: 26459156.
6: Fritz BM, Boehm SL 2nd. Adenosinergic regulation of binge-like ethanol drinking and associated locomotor effects in male C57BL/6J mice. Pharmacol Biochem Behav. 2015 Aug;135:83-9. doi: 10.1016/j.pbb.2015.05.016. Epub 2015 May 29. PubMed PMID: 26033424; PubMed Central PMCID: PMC4492850.
7: Fuzzati-Armentero MT, Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti G, Blandini F, Baqi Y, Müller CE, Volpini R, Costa G, Simola N, Pinna A. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson’s disease. J Neurochem. 2015 Aug;134(4):740-7. doi: 10.1111/jnc.13162. Epub 2015 Jun 4. PubMed PMID: 25962878.
8: Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, Malik E, Mariciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, D’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L, Blum D. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry. 2016 Jan;21(1):97-107. doi: 10.1038/mp.2014.151. Epub 2014 Dec 2. Erratum in: Mol Psychiatry. 2016 Jan;21(1):149. Mariciniak, E [Corrected to Marciniak, E]. PubMed PMID: 25450226.
9: Yohn SE, Thompson C, Randall PA, Lee CA, Müller CE, Baqi Y, Correa M, Salamone JD. The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology (Berl). 2015 Apr;232(7):1313-23. doi: 10.1007/s00213-014-3766-0. Epub 2014 Oct 17. PubMed PMID: 25323625.
10: Clissold KA, Pratt WE. The effects of nucleus accumbens μ-opioid and adenosine 2A receptor stimulation and blockade on instrumental learning. Behav Brain Res. 2014 Nov 1;274:84-94. doi: 10.1016/j.bbr.2014.07.047. Epub 2014 Aug 4. PubMed PMID: 25101542; PubMed Central PMCID: PMC4181594.
11: Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B, Shah P, Pandit S, Vemuri VK, Makriyannis A, Baqi Y, Müller CE, Correa M, Salamone JD. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One. 2014 Jun 17;9(6):e99320. doi: 10.1371/journal.pone.0099320. eCollection 2014. PubMed PMID: 24937131; PubMed Central PMCID: PMC4061002.
12: Justinová Z, Redhi GH, Goldberg SR, Ferré S. Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on Δ9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys. J Neurosci. 2014 May 7;34(19):6480-4. doi: 10.1523/JNEUROSCI.5073-13.2014. PubMed PMID: 24806674; PubMed Central PMCID: PMC4012307.
13: Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti GF, Franco R, Lanciego JL, Baqi Y, Müller CE, Pinna A, Blandini F, Armentero MT. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. J Neuropathol Exp Neurol. 2014 May;73(5):414-24. doi: 10.1097/NEN.0000000000000064. PubMed PMID: 24709676.
14: Nichols NL, Johnson RA, Satriotomo I, Mitchell GS. Neither serotonin nor adenosine-dependent mechanisms preserve ventilatory capacity in ALS rats. Respir Physiol Neurobiol. 2014 Jun 15;197:19-28. doi: 10.1016/j.resp.2014.03.005. Epub 2014 Mar 28. PubMed PMID: 24681328; PubMed Central PMCID: PMC4022482.
15: Pinna A, Bonaventura J, Farré D, Sánchez M, Simola N, Mallol J, Lluís C, Costa G, Baqi Y, Müller CE, Cortés A, McCormick P, Canela EI, Martínez-Pinilla E, Lanciego JL, Casadó V, Armentero MT, Franco R. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol. 2014 Mar;253:180-91. doi: 10.1016/j.expneurol.2013.12.021. Epub 2014 Jan 9. PubMed PMID: 24412491.
16: Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y, Müller CE, López-Cruz L, Correa M, Salamone JD. Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci. 2013 Dec 4;33(49):19120-30. doi: 10.1523/JNEUROSCI.2730-13.2013. PubMed PMID: 24305809; PubMed Central PMCID: PMC3850037.
17: Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, Baqi Y, Müller CE, Correa M, Salamone JD. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology (Berl). 2014 Feb;231(4):727-36. doi: 10.1007/s00213-013-3285-4. Epub 2013 Oct 18. PubMed PMID: 24136220; PubMed Central PMCID: PMC4468782.
18: Podurgiel SJ, Nunes EJ, Yohn SE, Barber J, Thompson A, Milligan M, Lee CA, López-Cruz L, Pardo M, Valverde O, Lendent C, Baqi Y, Müller CE, Correa M, Salamone JD. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor. Neuroscience. 2013 Oct 10;250:507-19. doi: 10.1016/j.neuroscience.2013.07.008. Epub 2013 Jul 15. PubMed PMID: 23867769.
19: Collins-Praino LE, Paul NE, Ledgard F, Podurgiel SJ, Kovner R, Baqi Y, Müller CE, Senatus PB, Salamone JD. Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism. Eur J Neurosci. 2013 Jul;38(1):2183-91. doi: 10.1111/ejn.12212. Epub 2013 Apr 18. PubMed PMID: 23600953.
20: Pardo M, López-Cruz L, Valverde O, Ledent C, Baqi Y, Müller CE, Salamone JD, Correa M. Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice. Behav Brain Res. 2013 Jun 15;247:217-26. doi: 10.1016/j.bbr.2013.03.035. Epub 2013 Apr 1. PubMed PMID: 23557694.